

Rozanolixizumab Biochemical

Rozanolixizumab

CATALOG #
AAA227805

PRODUCT SYNONYMS

Rozanolixizumab; Rozanolixizumab biochemical

PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1584645-37-3
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Intravenous (IV) rozanolixizumab dosing in cynomolgus monkeys demonstrated non-linear pharmacokinetics indicative of target-mediated drug disposition; single IV rozanolixizumab doses (30 mg/kg) in cynomolgus monkeys reduced plasma IgG concentration by 69% by Day 7 post-administration. Daily IV administration of rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter) reduced plasma IgG concentrations in all cynomolgus monkeys, with low concentrations maintained throughout the treatment period (42 days)[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Cyclooctyne-O-amido-PEG3-PFP ester, CAS 2101206-33-9



Structure
Cyclooctyne-O-amido-PEG3-PFP ester, CAS 2101206-33-9

ADDITIONAL INFORMATION

Related Product Information for Rozanolixizumab biochemical	Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.
References	1. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/rozanolixizumab/227805>